You are here
Home > DRGT

DRGT USA Announces Appointment of Dr. Elizabeth Manning Duus, as Executive Director of Clinical Development

NEW YORK, Feb. 05, 2019 (GLOBE NEWSWIRE) — Druggability Technologies USA today announced the expansion of the clinical team, with the addition of Dr. Elizabeth Manning Duus, who has been named Executive Director, Clinical Development. Druggability Technologies USA has been engaged by Druggability Technologies Holdings (DRGT) to assist with the clinical development of all human […]

Best in Class Erectile Dysfunction Drug – DRGT announces dose escalation study results of its Super-Tadalafil DRGT-99

MALTA, May 02, 2018 (GLOBE NEWSWIRE) — DRGT, a specialty pharmaceutical company with a proprietary formulation technology, announced the results of its successful dose escalation PK study for DRGT-99, an innovative formulation of tadalafil. Tadalafil (Cialis®) was originally developed by Lilly ICOS, LLC –a longer lasting alternative to Sildenafil Citrate (Viagra®) and is indicated for […]

DRGT announces results of Phase I study expanding clinical utility of the drug Sirolimus utilizing the company’s novel Super-API technology platform

MSIDA, Malta, Oct. 05, 2017 (GLOBE NEWSWIRE) — DRGT, a specialty pharmaceutical company, today announced the results of its Phase I study of DRGT18-2, a novel formulation of Sirolimus (Rapamune®), originally a Pfizer product approved by the FDA. Sirolimus, as developed by Pfizer and approved by the FDA, initially failed to achieve sufficient therapeutic effect […]